HGH FRAGMENT 176-191 5

### HGH FRAGMENT 176-191 (HGH fragment 176-191) for Injection

**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use HGH FRAGMENT 176-191 safely and effectively. See full prescribing information for HGH FRAGMENT 176-191.

HGH FRAGMENT 176-191 injection, for subcutaneous use

**INDICATIONS AND USAGE**
HGH FRAGMENT 176-191 is a modified growth hormone peptide indicated for investigational use in targeting fat loss without affecting growth or insulin in performance enhancement settings. Not approved for human therapeutic use in many jurisdictions; consult local regulations (1).

**DOSAGE AND ADMINISTRATION**
– Reconstitute lyophilized powder with bacteriostatic water.
– Adult males: 200 mcg to 500 mcg per day.
– Adult females: 200 mcg to 400 mcg per day (2.1).
– Cycle duration: Typically 4 to 8 weeks for cutting.

**DOSAGE FORMS AND STRENGTHS**
Lyophilized powder: 5 mg per vial (3).

**CONTRAINDICATIONS**
– Hypersensitivity to HGH fragment 176-191 or any component of the formulation (4).

**WARNINGS AND PRECAUTIONS**
– Immunogenicity: Potential for antibody formation; monitor for allergic reactions (5.1).
– Injection site reactions: Monitor for irritation or swelling (5.2).
– Limited long-term safety data: Use cautiously in chronic conditions (5.3).

**ADVERSE REACTIONS**
Common adverse reactions include injection site pain, mild fatigue, and localized redness (6).

**DRUG INTERACTIONS**
– Limited known interactions; monitor with other peptides (7.1).

**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Insufficient data; avoid use (8.1).
– Lactation: Excretion unknown; not recommended (8.2).
– Pediatric use: Safety not established (8.4).
– Geriatric use: Monitor for organ dysfunction (8.5).

Revised: 08/2025

**FULL PRESCRIBING INFORMATION**

**1 INDICATIONS AND USAGE**
HGH FRAGMENT 176-191 is indicated for investigational use in adults to target stubborn fat reduction, increase lipolysis without muscle loss, improve energy and metabolism, and enhance skin and recovery without affecting blood sugar or growth. It is commonly used in cutting cycles for weight management. This product is not approved for clinical use and should be administered under medical supervision.

**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Reconstitute 5 mg vial with 1-2 mL bacteriostatic water. Administer subcutaneously, preferably in the abdomen or thigh.
– Males: 200 mcg to 500 mcg daily, in one or two divided doses.
– Females: 200 mcg to 400 mcg daily, in one or two divided doses.
– Cycle duration: Typically 4 to 8 weeks, adjusted based on response and tolerance. Discontinue if adverse effects occur.

**2.2 Preparation and Handling**
Use sterile technique to reconstitute and draw doses. Inspect reconstituted solution for clarity; do not use if discolored or particulate matter is present.

**3 DOSAGE FORMS AND STRENGTHS**
Supplied as lyophilized powder containing 5 mg HGH fragment 176-191 per single-use vial.

**4 CONTRAINDICATIONS**
HGH FRAGMENT 176-191 is contraindicated in:
– Patients with known hypersensitivity to HGH fragment 176-191 or excipients (e.g., mannitol).

**5 WARNINGS AND PRECAUTIONS**
**5.1 Immunogenicity**
As a synthetic peptide, HGH FRAGMENT 176-191 may induce antibody formation, potentially leading to hypersensitivity reactions such as rash or anaphylaxis. Monitor for signs of allergic response and discontinue if severe reactions occur.
**5.2 Injection Site Reactions**
May cause localized pain, redness, or swelling at the injection site. Rotate injection sites and monitor for signs of infection or severe reactions.
**5.3 Limited Long-Term Safety Data**
Long-term effects in humans are not well-established; use with caution in patients with chronic conditions or for prolonged periods. Regular monitoring is recommended.

**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– Local: Injection site pain, erythema, or swelling.
– General: Mild fatigue, headache.
– Metabolic: Transient changes in energy levels.
Serious reactions are rare but may include hypersensitivity responses.

**7 DRUG INTERACTIONS**
**7.1 Other Peptides**
Concurrent use with other growth hormone-related peptides may alter metabolic effects. Monitor for unexpected interactions and adjust therapy as needed.

**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
No adequate studies in pregnant women; potential risks to the fetus are unknown. Avoid use during pregnancy.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Safety and efficacy not established in pediatric patients; use is not recommended.
**8.5 Geriatric Use**
Limited data available; monitor for age-related organ dysfunction, particularly metabolic or cardiovascular issues.

**9 DRUG ABUSE AND DEPENDENCE**
No evidence of abuse or dependence potential with HGH FRAGMENT 176-191, but misuse for performance enhancement may occur. Monitor for inappropriate use.

**10 OVERDOSAGE**
No specific data on overdose; symptoms may include exaggerated fatigue or injection site reactions. Treat symptomatically and discontinue use immediately.

**11 DESCRIPTION**
HGH FRAGMENT 176-191 is a modified growth hormone peptide targeting lipolysis. It is supplied as a white lyophilized powder, soluble in bacteriostatic water for injection. Each vial contains 5 mg HGH fragment 176-191, with mannitol as a stabilizer. Half-life: Approximately 30 minutes. Note: Ethyl oleate and ricinus oil are not used in this formulation, as it is water-based.

**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
HGH FRAGMENT 176-191 mimics the lipolytic portion of growth hormone, promoting fat breakdown without affecting growth or insulin levels.
**12.3 Pharmacokinetics**
Rapidly absorbed after subcutaneous injection; short half-life of approximately 30 minutes; metabolized and excreted rapidly, primarily via urine.

**13 NONCLINICAL TOXICOLOGY**
Limited data available; animal studies suggest low toxicity. No human carcinogenicity data available.

**16 HOW SUPPLIED/STORAGE AND HANDLING**
5 mg lyophilized powder in single-use vials. Store refrigerated at 2°-8°C (36°-46°F). Reconstituted solution stable for up to 14 days refrigerated. Protect from light. Keep out of reach of children.

*Manufactured by: Medi Pharma*